What Are Cancer Markers and What Can They Detect?
Cancer marker blood tests measure certain substances that may be associated with specific cancers. Learn what AFP, CEA, CA19-9, PSA, CA125, CA15-3 and CA72-4 can indicate, when doctors use them and why results need careful interpretation.
Explore Health Screening PackagesQuick Answer: What Do Cancer Marker Tests Detect?
Cancer markers, also called tumour markers, are substances that may be produced by cancer cells or by the body in response to cancer. Blood tests can measure certain markers, including AFP, CEA, CA19-9, PSA, CA125, CA15-3 and CA72-4.
These markers are associated with different cancers and may help doctors assess certain conditions, monitor an established cancer or evaluate treatment response. However, an elevated result does not automatically mean cancer, and a normal result cannot rule it out.
Most tumour marker blood tests are not suitable as standalone screening tests for people without symptoms. Doctors interpret the results alongside medical history, examination, imaging and, when necessary, a biopsy.
Blood tests are commonly included in health assessments because they can provide useful information about different aspects of health. Some blood tests also measure substances known as cancer markers or tumour markers.
If you are considering a cancer marker blood test in Johor Bahru, it is important to understand what these tests can and cannot tell you. Different markers are associated with different types of cancer, and no single marker can detect every cancer.
This guide explains the common tumour markers available at Southern Health Centre, their potential clinical uses and the limitations you should understand before interpreting a result.
Understanding the Basics
1. What Are Cancer Markers?
Cancer markers, also known as tumour markers, are substances that can sometimes be found at higher levels in the blood, urine or body tissues of people with certain cancers.
They may be produced directly by cancer cells or by normal cells in response to a cancer. Many are proteins or other substances that can be measured through laboratory testing.
Examples include alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9) and prostate-specific antigen (PSA).
Are Cancer Markers the Same as a Cancer Diagnosis?
No. A tumour marker result is only one piece of medical information. It may help guide further assessment, but it cannot independently confirm whether someone has cancer or identify the exact location of a cancer.
How Are Cancer Markers Measured?
Many common tumour marker tests are performed using a blood sample. The laboratory measures the concentration of a particular substance in the sample and reports the result against the laboratory's reference range or clinical decision threshold.
The type of test depends on the marker being assessed. Different laboratories may use different testing methods and reference ranges, so results should be interpreted using the report provided by the testing laboratory.
What the Tests May Indicate
2. What Can Cancer Markers Detect?
Different tumour markers are associated with different cancers. Some may help doctors investigate a suspected condition, while others are more commonly used to monitor people who have already been diagnosed.
Liver and Germ Cell Tumours
AFP may be elevated in certain liver cancers and some germ cell tumours. It can support clinical assessment and monitoring in appropriate patients.
Colorectal and Digestive Cancers
CEA and CA19-9 may be associated with certain digestive system cancers. They are often used to monitor selected patients rather than to screen the general population.
Prostate Cancer
PSA is a marker used in the assessment of prostate health. An elevated result may occur in prostate cancer, but also in several non-cancerous prostate conditions.
Ovarian and Breast Cancers
CA125 may be associated with ovarian cancer, while CA15-3 may be used to monitor certain people with breast cancer. Neither is suitable as a general screening test on its own.
Gastric and Other Cancers
CA72-4 may be associated with gastric cancer and certain other malignancies. Its use depends on the clinical situation and it is not a standalone cancer detection test.
Important: A marker being associated with a particular cancer does not mean that it can reliably detect that cancer in everyone. The usefulness of each test depends on the person's medical history, symptoms, risk factors and clinical assessment.
Common Blood Tests
3. Common Cancer Marker Blood Tests and What They Mean
The following tumour markers are available in the cancer marker testing options at Southern Health Centre. Each marker has different clinical uses and limitations.
| Marker | Common Associations | How It May Be Used | Important Limitations |
|---|---|---|---|
| AFP | Hepatocellular carcinoma (a type of liver cancer) and certain germ cell tumours, including some testicular and ovarian tumours. | May support assessment in selected patients and help monitor treatment response or disease progression in certain established cancers. | Can also be elevated in chronic liver disease, hepatitis and pregnancy. Not suitable as a general cancer screening test. |
| CEA | Most commonly associated with colorectal cancer. It may also be elevated in some pancreatic, gastric, lung and breast cancers. | Mainly used to monitor treatment response and possible recurrence in selected people with an established cancer, particularly colorectal cancer. | Smoking and non-cancerous conditions, including liver and digestive system disorders, may affect levels. Not recommended as a general colorectal cancer screening test. |
| CA19-9 | Pancreatic cancer and cancers of the bile ducts and gallbladder. It may also be associated with some gastric cancers. | Often used to monitor disease activity and treatment response in selected patients with an established cancer. | Can rise due to bile duct obstruction, inflammation, pancreatitis and other non-cancerous conditions. Some people do not produce CA19-9 even when cancer is present. |
| PSA (Male) |
Prostate cancer. PSA is a protein produced by cells in the prostate gland. | May be used in discussions about prostate cancer screening, further investigation and monitoring after diagnosis or treatment. | Levels may rise due to benign prostate enlargement, prostatitis, urinary infection and other factors. An elevated result does not confirm prostate cancer. |
| CA125 (Female) |
Ovarian, fallopian tube and primary peritoneal cancers. | May support the assessment of a suspected ovarian condition and help monitor treatment response or recurrence in selected patients. | Can also rise due to menstruation, pregnancy, endometriosis, fibroids and pelvic inflammation. Not recommended as a general screening test for ovarian cancer. |
| CA15-3 (Female) |
Most commonly associated with breast cancer, particularly in people with advanced or metastatic disease. | May be used alongside other assessments to monitor treatment response or disease progression in selected patients with breast cancer. | Not suitable for breast cancer screening or diagnosis on its own. Some people with breast cancer may have normal CA15-3 levels. |
| CA72-4 | Most commonly associated with gastric cancer. It may also be elevated in certain ovarian and other gastrointestinal malignancies. | May be used as an additional marker in selected clinical situations, sometimes alongside other investigations or markers. | It is not specific to one cancer and is not a standalone screening or diagnostic test. Its clinical usefulness varies by condition. |
The associations above are not exclusive. A marker may be elevated in more than one type of cancer or in non-cancerous conditions. Doctors therefore consider the overall clinical picture rather than relying on a single result.
Understanding the Different Markers
AFP: Alpha-Fetoprotein
AFP is a protein normally produced during foetal development. In adults, higher levels may be associated with hepatocellular carcinoma and certain germ cell tumours.
Doctors may use AFP as part of the assessment of people with certain liver conditions or known cancers. In selected people at increased risk of liver cancer, AFP may be considered together with liver ultrasound as part of surveillance. AFP alone cannot reliably confirm or exclude liver cancer.
CEA: Carcinoembryonic Antigen
CEA is a protein that may be elevated in colorectal cancer and some other cancers. It is particularly useful in monitoring certain patients after a colorectal cancer diagnosis.
Doctors may compare CEA levels over time to assess treatment response or investigate possible recurrence. However, CEA is not recommended as a standalone test to screen people without symptoms for colorectal cancer.
CA19-9: Cancer Antigen 19-9
CA19-9 is commonly associated with pancreatic and biliary tract cancers. It may be used to monitor certain people with an established diagnosis and assess changes during treatment.
However, conditions such as bile duct obstruction, cholangitis and pancreatitis can also increase CA19-9 levels. It is not suitable for general pancreatic cancer screening.
PSA: Prostate-Specific Antigen (Male)
PSA is a protein produced by the prostate gland. A PSA blood test measures the amount of this protein in the blood and may help assess prostate health.
Higher PSA levels can occur in prostate cancer, but they can also be caused by benign prostate enlargement, inflammation or infection. PSA testing may be considered for prostate cancer screening after discussing the possible benefits, limitations and follow-up procedures with a doctor.
CA125: Cancer Antigen 125 (Female)
CA125 is a protein that may be elevated in ovarian and related cancers. Doctors may use it alongside imaging and clinical assessment when investigating a suspected ovarian condition or monitoring certain patients after diagnosis.
CA125 can also increase due to non-cancerous conditions such as endometriosis, uterine fibroids, menstruation and pregnancy. It is not recommended as a general screening test for ovarian cancer in people at average risk who have no symptoms.
CA15-3: Cancer Antigen 15-3 (Female)
CA15-3 is a marker that may be elevated in some people with breast cancer, particularly when the disease has spread beyond the breast.
It may help doctors monitor treatment response or disease progression in selected patients. However, CA15-3 is not a substitute for mammography, breast examination or biopsy, and it is not recommended as a standalone breast cancer screening test.
CA72-4: Cancer Antigen 72-4
CA72-4 is a tumour-associated marker that may be elevated in gastric cancer and some other malignancies, including certain ovarian tumours.
It may be considered as an additional marker in selected clinical assessments. However, it is not specific to one cancer and cannot independently diagnose or rule out gastric cancer.
Interpreting Your Blood Test
4. How to Understand Your Cancer Marker Test Results
A cancer marker report usually shows a measured value and a reference range or decision threshold. The result may be described as within range or elevated, depending on the laboratory's testing method and reporting criteria.
However, a result should not be interpreted without considering the person's health history and clinical circumstances.
Elevated Cancer Marker
A higher-than-expected result may indicate that further assessment is needed. It does not automatically mean that cancer is present.
Infections, inflammation, benign growths, liver conditions and other non-cancerous conditions may affect certain markers.
Normal Cancer Marker
A result within the laboratory's reference range does not guarantee that cancer is absent.
Some cancers do not produce detectable levels of a particular marker, especially during earlier stages. A normal result should not replace recommended screening or medical assessment.
Do not diagnose yourself based on a tumour marker result. If your result is outside the reference range, discuss it with a doctor. The next step may involve reviewing your medical history, repeating a test, arranging imaging or conducting other investigations, depending on the circumstances.
Important Considerations
5. What Are the Limitations of Tumour Marker Tests?
Although tumour marker blood tests can provide useful clinical information, they have limitations. Understanding these limitations helps prevent unnecessary worry and false reassurance.
1. Elevated Levels Do Not Always Mean Cancer
Certain non-cancerous conditions can increase tumour marker levels. For example, CA125 may rise during menstruation or with endometriosis, while PSA may increase due to benign prostate enlargement or inflammation.
2. Normal Levels Do Not Rule Out Cancer
Not every cancer produces a measurable amount of a particular marker. Some people with cancer may have normal marker levels, particularly in earlier stages or when the cancer does not produce that marker.
3. A Marker May Be Associated with More Than One Condition
Many tumour markers are not specific to a single cancer. For example, CEA may be elevated in several cancers and certain non-cancerous conditions. This means the result cannot identify the cancer's location by itself.
4. Not All Tumour Markers Are Suitable for Screening
A screening test is intended to identify possible disease before symptoms develop. Most tumour marker blood tests are not sufficiently accurate to be used alone for general population cancer screening.
5. Trends May Matter More Than One Result
For people already diagnosed with certain cancers, doctors may compare marker levels over time. Changes can provide useful information about treatment response or possible disease progression, but they still need to be interpreted alongside other clinical findings.
Knowing the Difference
6. Cancer Screening vs Diagnosis vs Monitoring
Cancer screening, cancer diagnosis and cancer monitoring are different medical purposes. A tumour marker test may be useful in one situation but not necessarily appropriate in another.
| Purpose | What It Means | Examples |
|---|---|---|
| Cancer Screening | Testing people who do not have symptoms to identify possible cancer or precancerous changes. | Mammography for breast cancer screening, cervical screening with HPV testing or Pap testing, and colorectal screening with appropriate stool tests or colonoscopy. |
| Cancer Diagnosis | Investigations performed when symptoms, examination findings or other test results raise concern about cancer. | Clinical examination, imaging, laboratory tests and tissue biopsy where appropriate. |
| Cancer Monitoring | Following an established cancer to assess changes over time or evaluate treatment response. | Serial CEA measurements in selected colorectal cancer patients or CA15-3 measurements in selected breast cancer patients. |
Why Are Tumour Markers Not a Replacement for Cancer Screening?
Evidence-based cancer screening uses tests selected for specific cancers and appropriate age or risk groups. Tumour marker blood tests generally do not have the accuracy needed to replace these established screening methods in people without symptoms.
Further Medical Assessment
7. Why Are Other Tests Needed to Assess Cancer?
A tumour marker result is usually considered alongside other medical information. Depending on the suspected condition, a doctor may recommend additional investigations to understand the cause of an abnormal result or assess a possible cancer.
Medical History and Physical Examination
A doctor reviews symptoms, personal and family medical history, risk factors and relevant physical examination findings.
Imaging Investigations
Depending on the clinical concern, ultrasound, X-ray, CT, MRI or other imaging may be used to examine organs and identify abnormal areas.
Additional Laboratory Tests
Other blood or urine tests may help assess organ function, inflammation or alternative explanations for an abnormal tumour marker result.
Biopsy and Laboratory Examination
When cancer is suspected, a biopsy may be required. A pathologist examines the collected tissue to determine whether cancer cells are present and, where possible, identify the cancer type.
Not everyone with an elevated tumour marker needs every investigation listed above. The appropriate next step depends on the specific marker, the level, the person's risk factors and the doctor's assessment.
Who Should Consider Testing?
8. Who May Need a Cancer Marker Test?
Tumour marker tests are most useful when there is a clear clinical reason for ordering them. A doctor may consider these tests in situations such as:
- Monitoring an established cancer: Certain markers may help follow treatment response or disease progression when the cancer is known to produce that marker.
- Investigating a suspected condition: A marker may form part of a wider assessment when symptoms, imaging or other findings raise concern.
- Assessing selected higher-risk individuals: Some people with particular medical conditions or risk factors may require specific surveillance plans determined by their doctor.
- Assessing prostate health: PSA testing may be discussed with eligible men after considering age, family history, personal risk and the possible benefits and harms of screening.
When should you seek medical advice? Do not rely on tumour marker testing alone if you have persistent or unexplained symptoms such as an unusual lump, unexplained weight loss, abnormal bleeding, persistent abdominal bloating, ongoing changes in bowel habits or other concerning changes. Arrange a medical assessment even if a previous tumour marker result was normal.
Local Health Screening
9. Cancer Marker Tests at Southern Health Centre in Johor Bahru
If you are looking for health screening in Johor Bahru, Southern Health Centre offers health screening packages with selected tumour marker tests.
The tumour markers available include:
General Tumour Markers
- AFP
- CEA
- CA19-9
- CA72-4
Male Tumour Marker
- PSA (Prostate-Specific Antigen)
Female Tumour Markers
- CA125
- CA15-3
These markers cover different clinical associations, including liver, digestive system, prostate, ovarian and breast cancers. However, they should not be considered a complete cancer screening programme or a test that can detect all cancers.
Choosing a Suitable Health Screening Package
A package with more tests is not necessarily more suitable for everyone. Your age, medical history, family history, symptoms and individual risk factors should guide the choice of screening tests.
Discuss your health concerns with a healthcare professional before deciding which tumour markers or other investigations are appropriate.
Explore the available options on our Health Screening Packages in Johor Bahru page.
Common Questions
10. Frequently Asked Questions About Cancer Marker Tests
Can a cancer marker blood test detect cancer early?
Some tumour markers may provide useful information in selected clinical situations, but most are not sufficiently accurate to be used alone for general early cancer screening. Established screening methods, such as mammography, cervical screening and colorectal screening, should be followed according to individual risk and recommended guidelines.
Does a high cancer marker level mean I have cancer?
No. An elevated tumour marker does not automatically mean cancer is present. Certain non-cancerous conditions, including inflammation, infection and benign growths, may also increase marker levels. A doctor needs to interpret the result alongside your medical history and other investigations.
Can a normal tumour marker result rule out cancer?
No. Some cancers do not produce detectable levels of a particular tumour marker. A normal result cannot guarantee that cancer is absent, so recommended screening and medical assessment should not be skipped.
What are the common cancer marker blood tests?
Common tumour marker tests include AFP, CEA, CA19-9, PSA, CA125, CA15-3 and CA72-4. Each is associated with different cancers and has different clinical uses. Their suitability depends on the person's medical circumstances.
Which cancer marker tests are available at Southern Health Centre?
The available markers include AFP, CEA, CA19-9 and CA72-4. PSA is listed for male testing, while CA125 and CA15-3 are listed for female testing. Please contact the clinic to confirm the exact tests included in your selected health screening package.
Can one blood test detect all types of cancer?
No. There is no single conventional tumour marker blood test that can reliably detect every type of cancer. Different markers are associated with different conditions, and some cancers do not produce measurable levels of known markers.
Are cancer marker tests suitable for people without symptoms?
Not all tumour marker tests are suitable for people without symptoms. Most are used for monitoring known cancers or supporting specific clinical assessments rather than general population screening. A doctor can advise whether a particular test is appropriate based on your age, risk factors and medical history.
Do I need to fast before a cancer marker blood test?
Fasting requirements depend on the other tests included in your health screening package. Some tumour marker tests do not usually require fasting on their own, but you should follow the preparation instructions provided by the clinic.
Can cancer marker tests confirm a cancer diagnosis?
No. Tumour marker tests cannot independently confirm a cancer diagnosis. Depending on the suspected condition, doctors may recommend imaging, further laboratory tests and a biopsy to establish a diagnosis.
What is the difference between CEA, CA19-9 and CA72-4?
CEA is commonly used to monitor selected patients with colorectal cancer. CA19-9 is often associated with pancreatic and biliary tract cancers and may help monitor established disease. CA72-4 may be associated with gastric and certain other cancers. None of these markers can independently diagnose or rule out cancer.
Understand Your Health Screening Options
Choosing suitable health screening tests starts with understanding your health needs and individual risk factors. Speak with Southern Health Centre to learn more about the available screening packages and tumour marker testing options in Johor Bahru.
View Health Screening Packages Enquire on WhatsAppMedical Disclaimer: This article is intended for general educational purposes and should not replace professional medical advice, diagnosis or treatment. Tumour marker results must be interpreted by a qualified healthcare professional in the context of an individual's medical history and other clinical findings. The availability of tests and package inclusions may change; please confirm details with Southern Health Centre.